SEC Form SC 13G/A filed by Rhythm Pharmaceuticals Inc. (Amendment)

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G/A

Under the Securities Exchange Act of 1934

(Amendment No. 5)*

RHYTHM PHARMACEUTICALS, INC. 

(Name of Issuer)

Common Stock, $0.001 par value per share

(Title of Class of Securities)

76243J105

(CUSIP Number)

December 31, 2023

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

¨  Rule 13d-1(b)

x Rule 13d-1(c)

¨  Rule 13d-1(d)

*The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

¹ The percentage calculation assumes that there are currently 59,096,454 outstanding shares of Common Stock of the Issuer, based on the Issuer’s Form 10-Q as filed with the Securities and Exchange Commission (“SEC”) on November 8, 2023.

² The percentage calculation assumes that there are currently 59,096,454 outstanding shares of Common Stock of the Issuer, based on the Issuer’s Form 10-Q as filed with the SEC on November 8, 2023.

³ The percentage calculation assumes that there are currently 59,096,454 outstanding shares of Common Stock of the Issuer, based on the Issuer’s Form 10-Q as filed with the SEC on November 8, 2023. 

⁴ The percentage calculation assumes that there are currently 59,096,454 outstanding shares of Common Stock of the Issuer, based on the Issuer’s Form 10-Q as filed with the SEC on November 8, 2023.

Item 1.

(a)            Name of Issuer:

Rhythm Pharmaceuticals, Inc. (the “Issuer”).

(b)            Address of the Issuer’s Principal Executive Offices:

222 Berkeley Street, 12^th Floor, Boston, MA 02116

Item 2.

(a)            Name of Person Filing:

The names of the persons filing this report (collectively, the “Reporting Persons”) are:

RA Capital Management, L.P. (“RA Capital”) 

Peter Kolchinsky

Rajeev Shah 

RA Capital Healthcare Fund, L.P. (the “Fund”)

(b)            Address of Principal Business Office:

The principal business office of the Reporting Persons is c/o RA Capital Management, L.P., 200 Berkeley Street, 18^th Floor, Boston, MA 02116.

(c)            Citizenship:

RA Capital and the Fund are Delaware limited partnerships. Dr. Kolchinsky and Mr. Shah are United States citizens.

(d)            Title and Class of Securities:

Common stock, $0.001 par value per share (“Common Stock”)

(e)            CUSIP Number:

76243J105

Item 3.            If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

Not applicable.

Item 4.    Ownership:

The information required by this item with respect to each Reporting Person is set forth in Rows 5 through 9 and 11 of the cover pages to this Schedule 13G/A. The ownership percentages reported are based on 59,096,454 total shares of Common Stock, as reported in the Issuer’s Form 10-Q filed with the Securities and Exchange Commission on November 8, 2023.

The Fund directly holds 5,330,412 shares of Common Stock.

RA Capital Healthcare Fund GP, LLC is the general partner of the Fund. The general partner of RA Capital is RA Capital Management GP, LLC, of which Dr. Kolchinsky and Mr. Shah are the controlling persons. RA Capital serves as investment adviser for the Fund and may be deemed a beneficial owner, for purposes of Section 13(d) of the Securities Exchange Act of 1934 (the “Act”), of any securities of the Issuer held by the Fund. The Fund has delegated to RA Capital the sole power to vote and the sole power to dispose of all securities held in the Fund’s portfolios, including the shares of the Issuer’s Common Stock reported herein.  Because the Fund has divested itself of voting and investment power over the reported securities it holds and may not revoke that delegation on less than 61 days’ notice, the Fund disclaims beneficial ownership of the securities it holds for purposes of Section 13(d) of the Act and therefore disclaim any obligation to report ownership of the reported securities under Section 13(d) of the Act. As managers of RA Capital, Dr. Kolchinsky and Mr. Shah may be deemed beneficial owners, for purposes of Section 13(d) of the Act, of any securities of the Issuer beneficially owned by RA Capital. RA Capital, Dr. Kolchinsky, and Mr. Shah disclaim beneficial ownership of the securities reported in this Schedule 13G/A other than for the purpose of determining their obligations under Section 13(d) of the Act, and the filing of this Schedule 13G/A shall not be deemed an admission that either RA Capital, Dr. Kolchinsky, or Mr. Shah is the beneficial owner of such securities for any other purpose.

Item 5.           Ownership of Five Percent or Less of a Class:

If this statement is being filed to report the fact that as of the date hereof the Reporting Persons have ceased to be the beneficial owner of more than five percent of the class of securities, check the following ¨.

Item 6.           Ownership of More than Five Percent on Behalf of Another Person:

Not applicable.

Item 7.          Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person:

Not applicable.

Item 8.           Identification and Classification of Members of the Group:

Not applicable.

Item 9.           Notice of Dissolution of Group:

Not applicable.

Item 10.         Certification:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a–11.

Exhibit List

Exhibit 1: Joint Filing Agreement

SIGNATURE

After reasonable inquiry and to the best of its knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct.